You just read:

First Subject Dosed in Phase 1 Clinical Study of Novel Selective MUSCARINIC M4 Agonist in Development to Treat Major Symptoms of Alzheimer's Disease

News provided by

Heptares Therapeutics

Aug 31, 2017, 19:01 ET